Shufro Rose & Co’s ImmuCell ICCC Stock Holding History

Shufro Rose & Co’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$222K	Hold	35,000	–	–	0.02%	275
2025 Q4	$215K	Sell	35,000 -26,028	-43%	-$153K	0.01%	268
2025 Q3	$292K	Hold	61,028	–	–	0.02%	241
2025 Q2	$292K	Hold	61,028	–	–	0.02%	237
2025 Q1	$292K	Hold	61,028	–	–	0.02%	240
2024 Q4	$314K	Sell	61,028 -1,380	-2%	-$5.5K	0.02%	222
2024 Q3	$303K	Hold	62,408	–	–	0.02%	236
2024 Q2	$303K	Hold	62,408	–	–	0.02%	236
2024 Q1	$331K	Hold	62,408	–	–	0.03%	221
2023 Q4	$333K	Hold	62,408	–	–	0.03%	208
2023 Q3	$333K	Hold	62,408	–	–	0.03%	207
2023 Q2	$312K	Hold	62,408	–	–	0.03%	219
2023 Q1	$319K	Hold	62,408	–	–	0.03%	221
2022 Q4	$381K	Hold	62,408	–	–	0.03%	201
2022 Q3	$467K	Sell	62,408 -19,629	-24%	-$160K	0.05%	165
2022 Q2	$713K	Sell	82,037 -9	-0%	-$78	0.06%	134
2022 Q1	$792K	Buy	82,046 +64,137	+358%	+$553K	0.06%	138
2021 Q4	$143K	Hold	17,909	–	–	0.01%	288
2021 Q3	$168K	Hold	17,909	–	–	0.01%	270
2021 Q2	$170K	Hold	17,909	–	–	0.01%	266
2021 Q1	$173K	Sell	17,909 -32,761	-65%	-$307K	0.01%	266
2020 Q4	$301K	Hold	50,670	–	–	0.03%	212
2020 Q3	$275K	Hold	50,670	–	–	0.03%	218
2020 Q2	$240K	Hold	50,670	–	–	0.02%	219
2020 Q1	$192K	Hold	50,670	–	–	0.02%	244
2019 Q4	$261K	Hold	50,670	–	–	0.02%	246
2019 Q3	$282K	Hold	50,670	–	–	0.03%	232
2019 Q2	$329K	Hold	50,670	–	–	0.03%	207
2019 Q1	$322K	Hold	50,670	–	–	0.03%	206
2018 Q4	$357K	Sell	50,670 -121	-0.2%	-$935	0.04%	187
2018 Q3	$423K	Buy	50,791 +2,000	+4%	+$14.4K	0.04%	190
2018 Q2	$333K	Hold	48,791	–	–	0.03%	216
2018 Q1	$342K	Hold	48,791	–	–	0.03%	211
2017 Q4	$429K	Sell	48,791 -1,000	-2%	-$8.18K	0.04%	176
2017 Q3	$324K	Buy	49,791 +5,600	+13%	+$36.7K	0.03%	215
2017 Q2	$324K	Hold	44,191	–	–	0.03%	198
2017 Q1	$244K	Hold	44,191	–	–	0.03%	225
2016 Q4	$263K	Hold	44,191	–	–	0.03%	212
2016 Q3	$342K	Buy	44,191 +2,000	+5%	+$14.6K	0.04%	189
2016 Q2	$291K	Hold	42,191	–	–	0.03%	201
2016 Q1	$289K	Buy	42,191 +2,000	+5%	+$13.3K	0.03%	208
2015 Q4	$297K	Hold	40,191	–	–	0.03%	192
2015 Q3	$239K	Sell	40,191 -9,277	-19%	-$75.7K	0.03%	212
2015 Q2	$388K	Sell	49,468 -1,500	-3%	-$10.3K	0.04%	178
2015 Q1	$320K	Sell	50,968 -2,000	-4%	-$12.6K	0.03%	201
2014 Q4	$257K	Hold	52,968	–	–	0.03%	218
2014 Q3	$263K	Hold	52,968	–	–	0.03%	215
2014 Q2	$233K	Buy	52,968 +1,105	+2%	+$4.65K	0.02%	219
2014 Q1	$248K	Hold	51,863	–	–	0.03%	214
2013 Q4	$221K	Hold	51,863	–	–	0.02%	229
2013 Q3	$245K	Buy	51,863 +600	+1%	+$2.35K	0.03%	205
2013 Q2	$192K	Buy	+51,263	New	+$184K	0.02%	228

Other funds holding ICCC

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Shufro Rose & Co's ICCC Position: Q1 2026 in Review

Shufro Rose & Co held its ImmuCell (ICCC) position steady in Q1 2026 at 35,000 shares worth $222K. The position accounts for 0.02% of the portfolio, ranked #275.

Shufro Rose & Co first reported a position in ICCC in Q2 2013 and has held it in 52 quarters since. The position peaked at $792K in Q1 2022. 27 funds tracked by Wall St. Rank hold ICCC as of Q1 2026.

Shufro Rose & Co held 35,000 shares of ImmuCell worth $222K as of Q1 2026.
Shufro Rose & Co left its ImmuCell share count unchanged in Q1 2026.
ImmuCell made up 0.02% of Shufro Rose & Co's portfolio in Q1 2026, its #275 holding.
Shufro Rose & Co first reported a position in ImmuCell in Q2 2013 and has held it in 52 quarters since.
Shufro Rose & Co's ImmuCell position peaked at $792K in Q1 2022.
27 funds tracked by Wall St. Rank held ImmuCell as of Q1 2026.

Based on Shufro Rose & Co's 13F filing for Q1 2026, filed 15 May 2026.